We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Oxford Biomedica Plc | LSE:OXB | London | Ordinary Share | GB00BDFBVT43 | ORD 50P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 14.60 | 7.67% | 205.00 | 202.00 | 205.00 | 203.00 | 192.00 | 196.00 | 256,526 | 16:35:04 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Medicinal Chems,botanicl Pds | 139.99M | -45.16M | -0.4676 | -4.33 | 195.58M |
From Apr 2021 to Apr 2024
TIDMOXB
RNS Number : 2108B
Oxford Biomedica PLC
08 June 2021
Grant of options
London, UK - 08 June 2021: Oxford Biomedica plc ("Oxford Biomedica" or the "Company") (LSE:OXB), a leading gene and cell therapy group announces that on 08 June 2021 nil-cost share options over ordinary shares of 50 pence each in the Company were granted under the Oxford Biomedica 2015 Deferred Bonus Plan ("DBP") and the Oxford Biomedica 2015 Long Term Incentive Plan ("LTIP").
2021 LTIP Awards
Hot Features
Premium
Name of individual Title Number Number Total shares Percentage
of shares of shares over which of current
subject subject options issued share
to the to the now held capital
2021 DBP 2021 LTIP under option
award award
Chief Executive
John Dawson Officer 20,221 80,460 848,393 1.0%
------------------ ----------- ----------- ------------- --------------
Chief Financial
Stuart Paynter Officer 11,642 47,966 247,902 0.3%
------------------ ----------- ----------- ------------- --------------
Chief Technical
James Miskin Officer 4,897 18,943 154,914 0.2%
------------------ ----------- ----------- ------------- --------------
Kyriacos Chief Scientific
Mitrophanous Officer 4,944 19,125 171,545 0.2%
------------------ ----------- ----------- ------------- --------------
Chief Operations
Nick Page Officer 5,170 19,999 89,436 0.1%
------------------ ----------- ----------- ------------- --------------
Chief People
Helen Stephenson-Ellis Officer 3,331 13,131 75,758 0.09%
------------------ ----------- ----------- ------------- --------------
Chief Business
Jason Slingsby Officer 4,595 18,114 108,867 0.1%
------------------ ----------- ----------- ------------- --------------
General
Natalie Walter Counsel 4,143 16,028 66,905 0.08%
------------------ ----------- ----------- ------------- --------------
Under the terms of the DBP, the DBP awards will become exercisable as to one third of the shares subject to each award on each of the first three anniversaries of the grant date.
The LTIP awards are subject to performance conditions. As set out in the 2020 Directors' Remuneration Report, the performance condition is based on TSR (40% of the award, assessed over the three years from grant); revenue growth (40% of the award, assessed over financial years 2021, 2022 and 2023) and strategic milestones (20% of the award). Details of the measures are included in the 2020 Directors' Remuneration Report, other than as regards the strategic milestones, which are commercially sensitive and will be disclosed in due course.
The LTIP awards granted to John Dawson and Stuart Paynter will "vest" following the assessment of the performance condition, but will only be "released" so that they can be exercised following the end of a further two year holding period. The2021 awards granted to other participants will vest and be released following the assessment of the performance condition.
The above table reflects the grant of an award (1,320) to rectify an administrative error in the 2020 LTIP award granted to the General Counsel and the lapse of an award (7,875) to rectify an administrative error in the 2020 LTIP award granted to the Chief Financial Officer ("CFO") on 26 June 2020. These amendments were also reflected in the Company's 2020 Report & Accounts.
RSU awards
In addition, on 08 June 2021 a nil-cost share option over 4,406 shares of 50 pence each in the Company was also granted under the LTIP scheme to Alexander Lewis, Chief of Staff. The RSU award is not subject to performance conditions and will become exercisable from the third anniversary of the grant date. The total shares over which options are held by Alexander Lewis is 69,227, representing 0.08% of the current issued share capital under option.
The current issued share capital of the Company is 82,555,443 ordinary shares of 50 pence each.
Notification of Dealing Form
1. Details of the Person Discharging Managerial Responsibility
("PDMR")/person closely associated with them ("PCA")
a) Name John Dawson
----------------------------- ------------------------------------------------
2. Reason for the notification
-------------------------------------------------------------------------------
a) Position/status Chief Executive Officer
----------------------------- ------------------------------------------------
b) Initial notification/ Initial Notification
amendment
----------------------------- ------------------------------------------------
3. Details of the Issuer
-------------------------------------------------------------------------------
a) Name Oxford Biomedica plc
----------------------------- ------------------------------------------------
b) LEI code 213800S1GVQNXQ15K851
----------------------------- ------------------------------------------------
4. Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of
transaction; (iii) each date; and (iv) each place
where transactions have been conducted
-------------------------------------------------------------------------------
a) Description of Ordinary Shares of 50 pence each
the financial ISIN: GB00BDFBVT43
instrument
Identification
code
----------------------------- ------------------------------------------------
b) Nature of the Grant of awards over Ordinary Shares
transaction under the Company's Long Term Incentive
Plan and Deferred Bonus Plan. No consideration
was paid for the grant of awards.
----------------------------- ------------------------------------------------
c) Price(s) and volumes(s) 2021 LTIP Award
Price Volume
Nil 80,460
-------
2021 DBP Award
Price Volume
Nil 20,221
-------
----------------------------- ------------------------------------------------
d) Aggregated information Awards granted over 100,681 shares
* Aggregate volume in total
N/A
* Price
----------------------------- ------------------------------------------------
e) Date of the transaction 2021-06-08
----------------------------- ------------------------------------------------
f) Place of the transaction Outside of trading venue
----------------------------- ------------------------------------------------
1. Details of the Person Discharging Managerial Responsibility
("PDMR")/person closely associated with them ("PCA")
a) Name Stuart Paynter
----------------------------- ------------------------------------------------
2. Reason for the notification
-------------------------------------------------------------------------------
a) Position/status Chief Financial Officer
----------------------------- ------------------------------------------------
b) Initial notification/ Initial Notification
amendment
----------------------------- ------------------------------------------------
3. Details of the Issuer
-------------------------------------------------------------------------------
a) Name Oxford Biomedica plc
----------------------------- ------------------------------------------------
b) LEI code 213800S1GVQNXQ15K851
----------------------------- ------------------------------------------------
4. Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of
transaction; (iii) each date; and (iv) each place
where transactions have been conducted
-------------------------------------------------------------------------------
a) Description of Ordinary Shares of 50 pence each
the financial ISIN: GB00BDFBVT43
instrument
Identification
code
----------------------------- ------------------------------------------------
b) Nature of the Grant of awards over Ordinary Shares
transaction under the Company's Long Term Incentive
Plan and Deferred Bonus Plan. No consideration
was paid for the grant of awards.
----------------------------- ------------------------------------------------
c) Price(s) and volumes(s) 2021 LTIP Award
Price Volume
Nil 47,966
-------
2021 DBP Award
Price Volume
Nil 11,642
-------
----------------------------- ------------------------------------------------
d) Aggregated information Awards granted over 59,608 shares in
* Aggregate volume total
N/A
* Price
----------------------------- ------------------------------------------------
e) Date of the transaction 2021-06-08
----------------------------- ------------------------------------------------
f) Place of the transaction Outside of trading venue
----------------------------- ------------------------------------------------
1. Details of the Person Discharging Managerial Responsibility
("PDMR")/person closely associated with them ("PCA")
a) Name James Miskin
----------------------------- ------------------------------------------------
2. Reason for the notification
-------------------------------------------------------------------------------
a) Position/status Chief Technical Officer
----------------------------- ------------------------------------------------
b) Initial notification/ Initial Notification
amendment
----------------------------- ------------------------------------------------
3. Details of the Issuer
-------------------------------------------------------------------------------
a) Name Oxford Biomedica plc
----------------------------- ------------------------------------------------
b) LEI code 213800S1GVQNXQ15K851
----------------------------- ------------------------------------------------
4. Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of
transaction; (iii) each date; and (iv) each place
where transactions have been conducted
-------------------------------------------------------------------------------
a) Description of Ordinary Shares of 50 pence each
the financial ISIN: GB00BDFBVT43
instrument
Identification
code
----------------------------- ------------------------------------------------
b) Nature of the Grant of awards over Ordinary Shares
transaction under the Company's Long Term Incentive
Plan and Deferred Bonus Plan. No consideration
was paid for the grant of awards.
----------------------------- ------------------------------------------------
c) Price(s) and volumes(s) 2021 LTIP Award
Price Volume
Nil 18,943
-------
2021 DBP Award
Price Volume
Nil 4,897
-------
----------------------------- ------------------------------------------------
d) Aggregated information Awards granted over 23,840 shares in
* Aggregate volume total
N/A
* Price
----------------------------- ------------------------------------------------
e) Date of the transaction 2021-06-08
----------------------------- ------------------------------------------------
f) Place of the transaction Outside of trading venue
----------------------------- ------------------------------------------------
1. Details of the Person Discharging Managerial Responsibility
("PDMR")/person closely associated with them ("PCA")
a) Name Kyriacos Mitrophanous
----------------------------- ------------------------------------------------
2. Reason for the notification
-------------------------------------------------------------------------------
a) Position/status Chief Scientific Officer
----------------------------- ------------------------------------------------
b) Initial notification/ Initial Notification
amendment
----------------------------- ------------------------------------------------
3. Details of the Issuer
-------------------------------------------------------------------------------
a) Name Oxford Biomedica plc
----------------------------- ------------------------------------------------
b) LEI code 213800S1GVQNXQ15K851
----------------------------- ------------------------------------------------
4. Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of
transaction; (iii) each date; and (iv) each place
where transactions have been conducted
-------------------------------------------------------------------------------
a) Description of Ordinary Shares of 50 pence each
the financial ISIN: GB00BDFBVT43
instrument
Identification
code
----------------------------- ------------------------------------------------
b) Nature of the Grant of awards over Ordinary Shares
transaction under the Company's Long Term Incentive
Plan and Deferred Bonus Plan. No consideration
was paid for the grant of awards.
----------------------------- ------------------------------------------------
c) Price(s) and volumes(s) 2021 LTIP Award
Price Volume
Nil 19,125
-------
2021 DBP Award
Price Volume
Nil 4,944
-------
----------------------------- ------------------------------------------------
d) Aggregated information Awards granted over 24,069 shares in
* Aggregate volume total
N/A
* Price
----------------------------- ------------------------------------------------
e) Date of the transaction 2021-06-08
----------------------------- ------------------------------------------------
f) Place of the transaction Outside of trading venue
----------------------------- ------------------------------------------------
1. Details of the Person Discharging Managerial Responsibility
("PDMR")/person closely associated with them ("PCA")
a) Name Nick Page
----------------------------- ------------------------------------------------
2. Reason for the notification
-------------------------------------------------------------------------------
a) Position/status Chief Operations Officer
----------------------------- ------------------------------------------------
b) Initial notification/ Initial Notification
amendment
----------------------------- ------------------------------------------------
3. Details of the Issuer
-------------------------------------------------------------------------------
a) Name Oxford Biomedica plc
----------------------------- ------------------------------------------------
b) LEI code 213800S1GVQNXQ15K851
----------------------------- ------------------------------------------------
4. Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of
transaction; (iii) each date; and (iv) each place
where transactions have been conducted
-------------------------------------------------------------------------------
a) Description of Ordinary Shares of 50 pence each
the financial ISIN: GB00BDFBVT43
instrument
Identification
code
----------------------------- ------------------------------------------------
b) Nature of the Grant of awards over Ordinary Shares
transaction under the Company's Long Term Incentive
Plan and Deferred Bonus Plan. No consideration
was paid for the grant of awards.
----------------------------- ------------------------------------------------
c) Price(s) and volumes(s) 2021 LTIP Award
Price Volume
Nil 19,999
-------
2021 DBP Award
Price Volume
Nil 5,170
-------
----------------------------- ------------------------------------------------
d) Aggregated information Awards granted over 25,169 shares in
* Aggregate volume total
N/A
* Price
----------------------------- ------------------------------------------------
e) Date of the transaction 2021-06-08
----------------------------- ------------------------------------------------
f) Place of the transaction Outside of trading venue
----------------------------- ------------------------------------------------
1. Details of the Person Discharging Managerial Responsibility
("PDMR")/person closely associated with them ("PCA")
a) Name Helen Stephenson-Ellis
----------------------------- ------------------------------------------------
2. Reason for the notification
-------------------------------------------------------------------------------
a) Position/status Chief People Officer
----------------------------- ------------------------------------------------
b) Initial notification/ Initial Notification
amendment
----------------------------- ------------------------------------------------
3. Details of the Issuer
-------------------------------------------------------------------------------
a) Name Oxford Biomedica plc
----------------------------- ------------------------------------------------
b) LEI code 213800S1GVQNXQ15K851
----------------------------- ------------------------------------------------
4. Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of
transaction; (iii) each date; and (iv) each place
where transactions have been conducted
-------------------------------------------------------------------------------
a) Description of Ordinary Shares of 50 pence each
the financial ISIN: GB00BDFBVT43
instrument
Identification
code
----------------------------- ------------------------------------------------
b) Nature of the Grant of awards over Ordinary Shares
transaction under the Company's Long Term Incentive
Plan and Deferred Bonus Plan. No consideration
was paid for the grant of awards.
----------------------------- ------------------------------------------------
c) Price(s) and volumes(s) 2020 LTIP Award
Price Volume
Nil 13,131
-------
2021 DBP Award
Price Volume
Nil 3,331
-------
----------------------------- ------------------------------------------------
d) Aggregated information Awards granted over 16,462 shares in
* Aggregate volume total
N/A
* Price
----------------------------- ------------------------------------------------
e) Date of the transaction 2021-06-08
----------------------------- ------------------------------------------------
f) Place of the transaction Outside of trading venue
----------------------------- ------------------------------------------------
1. Details of the Person Discharging Managerial Responsibility
("PDMR")/person closely associated with them ("PCA")
a) Name Jason Slingsby
----------------------------- ------------------------------------------------
2. Reason for the notification
-------------------------------------------------------------------------------
a) Position/status Chief Business Officer
----------------------------- ------------------------------------------------
b) Initial notification/ Initial Notification
amendment
----------------------------- ------------------------------------------------
3. Details of the Issuer
-------------------------------------------------------------------------------
a) Name Oxford Biomedica plc
----------------------------- ------------------------------------------------
b) LEI code 213800S1GVQNXQ15K851
----------------------------- ------------------------------------------------
4. Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of
transaction; (iii) each date; and (iv) each place
where transactions have been conducted
-------------------------------------------------------------------------------
a) Description of Ordinary Shares of 50 pence each
the financial ISIN: GB00BDFBVT43
instrument
Identification
code
----------------------------- ------------------------------------------------
b) Nature of the Grant of awards over Ordinary Shares
transaction under the Company's Long Term Incentive
Plan and Deferred Bonus Plan. No consideration
was paid for the grant of awards.
----------------------------- ------------------------------------------------
c) Price(s) and volumes(s) 2021 LTIP Award
Price Volume
Nil 18,114
-------
2021 DBP Award
Price Volume
Nil 4,595
-------
----------------------------- ------------------------------------------------
d) Aggregated information Awards granted over 22,709 shares in
* Aggregate volume total
N/A
* Price
----------------------------- ------------------------------------------------
e) Date of the transaction 2021-06-08
----------------------------- ------------------------------------------------
f) Place of the transaction Outside of trading venue
----------------------------- ------------------------------------------------
1. Details of the Person Discharging Managerial Responsibility
("PDMR")/person closely associated with them ("PCA")
a) Name Natalie Walter
----------------------------- ------------------------------------------------
2. Reason for the notification
-------------------------------------------------------------------------------
a) Position/status General Counsel
----------------------------- ------------------------------------------------
b) Initial notification/ Initial Notification
amendment
----------------------------- ------------------------------------------------
3. Details of the Issuer
-------------------------------------------------------------------------------
a) Name Oxford Biomedica plc
----------------------------- ------------------------------------------------
b) LEI code 213800S1GVQNXQ15K851
----------------------------- ------------------------------------------------
4. Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of
transaction; (iii) each date; and (iv) each place
where transactions have been conducted
-------------------------------------------------------------------------------
a) Description of Ordinary Shares of 50 pence each
the financial ISIN: GB00BDFBVT43
instrument
Identification
code
----------------------------- ------------------------------------------------
b) Nature of the Grant of awards over Ordinary Shares
transaction under the Company's Long Term Incentive
Plan and Deferred Bonus Plan. No consideration
was paid for the grant of awards.
----------------------------- ------------------------------------------------
c) Price(s) and volumes(s) 2020 LTIP Award
Price Volume
Nil 16,028
-------
2021 DBP Award
Price Volume
Nil 4,143
-------
----------------------------- ------------------------------------------------
d) Aggregated information Awards granted over 20,171 shares in
* Aggregate volume total
N/A
* Price
----------------------------- ------------------------------------------------
e) Date of the transaction 2021-06-08
----------------------------- ------------------------------------------------
f) Place of the transaction Outside of trading venue
----------------------------- ------------------------------------------------
1. Details of the Person Discharging Managerial Responsibility
("PDMR")/person closely associated with them ("PCA")
a) Name Alexander Lewis
----------------------------- -------------------------------------
2. Reason for the notification
--------------------------------------------------------------------
a) Position/status Chief of Staff
----------------------------- -------------------------------------
b) Initial notification/ Initial Notification
amendment
----------------------------- -------------------------------------
3. Details of the Issuer
--------------------------------------------------------------------
a) Name Oxford Biomedica plc
----------------------------- -------------------------------------
b) LEI code 213800S1GVQNXQ15K851
----------------------------- -------------------------------------
4. Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of
transaction; (iii) each date; and (iv) each place
where transactions have been conducted
--------------------------------------------------------------------
a) Description of Ordinary Shares of 50 pence each
the financial ISIN: GB00BDFBVT43
instrument
Identification
code
----------------------------- -------------------------------------
b) Nature of the Grant of award over Ordinary Shares
transaction under the Company's Executive Share
Option Scheme. No consideration was
paid for the grant of awards.
----------------------------- -------------------------------------
c) Price(s) and volumes(s) 2021 RSU Award
Price Volume
Nil 4,406
-------
----------------------------- -------------------------------------
d) Aggregated information 4,406
* Aggregate volume N/A
* Price
----------------------------- -------------------------------------
e) Date of the transaction 2021-06-08
----------------------------- -------------------------------------
f) Place of the transaction Outside of trading venue
----------------------------- -------------------------------------
-Ends-
For further information, please contact: Oxford Biomedica plc: Tel: +44 (0)1865 783 000 Natalie Walter, Company Secretary
About Oxford Biomedica
Oxford Biomedica (LSE:OXB) is a leading, fully integrated, gene and cell therapy group focused on developing life changing treatments for serious diseases. Oxford Biomedica and its subsidiaries (the "Group") have built a sector leading lentiviral vector delivery platform (LentiVector(R) ), which the Group leverages to develop in vivo and ex vivo products both in-house and with partners. The Group has created a valuable proprietary portfolio of gene and cell therapy product candidates in the areas of oncology, ophthalmology, CNS disorders, liver diseases and respiratory disease. The Group has also entered into a number of partnerships, including with Novartis, Bristol Myers Squibb, Sio Gene Therapies, Orchard Therapeutics, Santen, Beam Therapeutics, Boehringer Ingelheim, the UK Cystic Fibrosis Gene Therapy Consortium and Imperial Innovations, through which it has long-term economic interests in other potential gene and cell therapy products. Additionally the group has signed a three year master supply and development agreement with AstraZeneca for large-scale manufacturing of the adenoviral based COVID-19 vaccine candidate, AZD1222. Oxford Biomedica is based across several locations in Oxfordshire, UK and employs more than 670 people. Further information is available at www.oxb.com
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
DSHFZGGVFRMGMZM
(END) Dow Jones Newswires
June 08, 2021 09:32 ET (13:32 GMT)
1 Year Oxford Biomedica Chart |
1 Month Oxford Biomedica Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
